Associations Between Circulating Interleukin-17 Levels and Systemic Lupus Erythematosus and Between Interleukin-17 Gene Polymorphisms and Disease Susceptibility: A Meta-analysis-Reference-Cited by-同舟云学术

Associations Between Circulating Interleukin-17 Levels and Systemic Lupus Erythematosus and Between Interleukin-17 Gene Polymorphisms and Disease Susceptibility: A Meta-analysis

Published:2020 Issue:1 Volume:27 Page:37
ISSN:2093-940X
Container-title:Journal of Rheumatic Diseases
language:en
Short-container-title:J Rheum Dis

Author:

Lee Young Ho¹^ORCID,Song Gwan Gyu¹

Affiliation:

1. Department of Rheumatology, Korea University College of Medicine, Seoul, Korea.

Publisher

Korean College of Rheumatology

Link

https://synapse.koreamed.org/pdf/10.4078/jrd.2020.27.1.37

Reference29 articles.

1. Systemic lupus erythematosus

2. Systemic Lupus Erythematosus

3. Genome-wide pathway analysis of genome-wide association studies on systemic lupus erythematosus and rheumatoid arthritis

4. IL-17 cytokine family

5. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Interleukin 17 in Egyptian Systemic Lupus Erythematosus Patients as a Biomarker in Disease Activity;Current Rheumatology Reviews;2024-12

2. Circulating leptin level in osteoarthritis and associations between leptin receptor polymorphisms and disease susceptibility: A meta‐analysis;International Journal of Rheumatic Diseases;2023-05-15

3. Association between Sodium Intake and Biopsychosocial Factors with Knee Joint Pain in Osteoarthritis patient;Research Journal of Pharmacy and Technology;2023-01-27

4. Associations between interleukin 17A and 17F polymorphisms and asthma susceptibility: A meta‐analysis;International Journal of Immunogenetics;2023-01-19

5. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis;Pharmacology;2023